<DOC>
	<DOCNO>NCT00993707</DOCNO>
	<brief_summary>The purpose study evaluate safety administer repeated dos CTX-100 ( formerly ETX-100 ) subject smoking-related chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Safety Study CTX-100 Inhalation Solution ( Formerly ETX-100 )</brief_title>
	<detailed_description>The study primarily aim establish safety evaluate biochemical activity CTX-100 ( formerly ETX-100 ) respect elastin breakdown , also concurrently gather data may point efficacy . The preliminary efficacy result use assist design subsequent phase 2b clinical study longer duration examine efficacy safety CTX-100 therapy chronic obstructive pulmonary disease .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Able willing provide write informed consent comply study requirement . Men woman age 40 75 year time consent . At least 10pack year ( average packs/day x number year ) cigarette use , either current smoker exsmoker . Diagnosis COPD screen consistent National Institutes Health guideline . Evidence emphysema chest xray . A ratio prebronchodilator FEV1 force vital capacity ( FVC ) ≤ 70 % screening . FEV1 ≥ 50 % ( prebronchodilator ) ≤ 79 % ( postbronchodilator ) predict normal screening . Clinical laboratory test ( complete blood count , serum chemistry , urinalysis ) within normal limit clinically acceptable PI/sponsor screening . Women childbearing potential men sexually active must agree use adequate method contraception ( oral contraceptive , depot progesterone , condom plus spermicide , IUD ) study 1 month final dose study drug . Subjects measure DLCO ≤ 50 % , unable perform reproducible DLCO . Subjects unable perform 3 reproducible spirometry test 5 attempt . Upper low respiratory tract infection within 2 week prior screen baseline ( day 1 ) . Presence clinically relevant abnormality chest xray ( evidence emphysema ) screening within previous 12 month . Use supplemental oxygen therapy . Requirement ventilatory support within last year . Exacerbation require treatment systemic corticosteroid within last 3 month . History lung transplant . Presence clinically relevant abnormality electrocardiogram ( ECG ) . Any medical condition , investigator 's judgment , would compromise study participation evaluation study drug . Women pregnant breastfeeding . Receipt investigational drug within 30 day prior screen ( include subject participate first phase study ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
</DOC>